The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific ...

The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.

Cambridge, USA-based clinical-stage biotechnology company Caldera Therapeutics, which is developing the first-in-class ...

Discover how Caldera International is transforming pet care with innovative heated and therapeutic solutions for improved comfort and health. CANBY, OR, UNITED STATES, January 6, 2026 ...